Spatial Genomics Market is expected to reach USD 490.86 million by 2030

Breast cancer is one of the most common cancers in the world. Breast cancer has the highest incidence of all cancers in women, according to a study published in January 2020. The study also stated that the annual incidence rate of breast cancer was over 1.6 million cases. This necessitates the use of early diagnostic procedures, which is where the role of particular genomics comes into play.

Data Bridge Market Research analyses that the spatial genomics market which is USD 204.01 million in 2022, is expected to reach USD 490.86 million by 2030, at a CAGR of 11.6% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Read More :
https://www.databridgemarketresearch.com/reports/global-spatial-genomics-market

Market Definition

Spatial genomics is the study of the entire set of genetic commands provided by DNA to detect and diagnose cancer tumour cells. Spatial genomics is used in disease control because it provides quantitative gene expression data. Spatial genomics also provides information on visualizing DNA and RNA mapping into tissue components.

Recent Developments

In 2020, Cancer Transcriptome Atlas, a new product based on NanoString Technologies' GeoMx Digital Spatial Profiler (DSP) platform, is optimized for readout on Illumina's next-generation sequencing (NGS) technology, is available.
In 2020, S2 Genomics launched the Singulator 100 System, which automates the processing of solid tissue samples into suspensions of single cells or nuclei with high yields and from small samples for a variety of single-cell biology and genomic analyses.

Some of the major players operating in the spatial genomics market are:

Thermo Fisher Scientific Inc. (U.S.)
10X Genomics (U.S.)
NanoString Technologies Inc. (U.S.)
Illumina Inc. (U.S.)
Bio-Rad Laboratories, Inc. (U.S.)
QIAGEN (Netherlands)
Agilent Technologies, Inc. (U.S.)
F. Hoffmann-La Roche Ltd. (Switzerland)
S2 Genomics, Inc. (U.S.)
Seven Bridges Genomics (U.S.)
CARTANA AB (Sweden)
READCOOR, INC (U.S.)
Advanced Cell Diagnostics, Inc. (U.S.)
Dovetail Genomics (U.S.)
Novartis AG (Switzerland)
Pfizer Inc. (U.S.)

More Links:

https://dbmrbuisness.blogspot.com/2023/06/global-blocking-buffers-market-industry.html

https://dbmrbuisness.blogspot.com/2023/06/global-reporter-tags-market-industry.html

https://dbmrbuisness.blogspot.com/2023/06/global-intra-uterine-therapies-market.html

https://dbmrbuisness.blogspot.com/2023/06/memory-disorders-market-will-grow-at.html

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Contact Us:-
Data Bridge Market research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
Email:- corporatesales@databridgemarketresearch.com

This release was published on openPR.